Retatrutide (a triple GIP/GLP-1/glucagon receptor agonist), survodutide, mazdutide, and CagriSema represent the next generation of anti-obesity compounds that may offer even greater efficacy or better tolerability profiles
Without those results, we remain a bit in the dark on basic questions like the ideal dosing or any subtle side effects in people
Thanks for checking out my page
It acts as a chemoattractant, recruiting immune cells like macrophages and mast cells to the site of investigation
DrWS: Yeah, so when youre going after big disease processes, when youre really starting to try to make a difference in Crohns or inflammatory bowel, things that are hot and not great, youre looking to hit them with everything youve got